Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.97 +0.02 (+2.53%)
As of: Sep 30, 2026 · 10:25 AM EDT

Lineage Cell Therapeutics (LCTX) EV to CFO (2022)

Updated

Lineage Cell Therapeutics' EV to CFO was 131.95 in Q4 2022, up 270.6% from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) EV to CFO (2022) Analysis & Trends

From Q1 2022 onward, Lineage Cell Therapeutics has reported EV to CFO for 4 quarters.

  • Per Business Quant data, LCTX's EV to CFO in the three quarters before Q4 2022 was 35.60 (Q3 2022), 47.28 (Q2 2022) and 31.23 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Lineage Cell Therapeutics 245.32 Mn 43.73 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 131.95
Sep 30, 2022 35.60
Jun 30, 2022 47.28
Mar 31, 2022 31.23
API Access

Lineage Cell Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=LCTX&period=max&api_key=YOUR_API_KEY